 |
Recent Updates in Anti-angiogenic Therapy for Metastatic Colorectal Cancer CME Heinz-Josef Lenz, MD, FACP; Al B. Benson III, MD, FACP; Axel Grothey, MD; Leonard Saltz, MD Author Information and Disclosures Release Date: July 2, 2008; Valid for credit through July 2, 2009 | Physicians - maximum of 2.5 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity was developed for distribution on Medscape.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity- Recent Updates in Anti-angiogenic Therapy for Metastatic Colorectal CancerHeinz-Josef Lenz, MD, FACP; Al B. Benson, III, MD, FACP; Axel Grothey, MD; Leonard Saltz, MD
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Albert Einstein College of Medicine |
|
|
Learning Objectives Upon completion of this activity, participants should be better able to: - List the current regimens used in first- and second-line treatment of metastatic colorectal cancer (mCRC)
- Describe the key takeaways from recent mCRC clinical trials
- Implement evidence-based strategies to safely
and effectively optimize chemotherapeutic and targeted agents in the first-line setting of mCRC
- Implement strategies to prevent and manage chemotherapy-induced neurotoxicity
- Identify predictive markers that may allow for better selection of treatment approaches for individual patients
- Understand the definition of resectable hepatic metastasis and the importance of integrating systemic therapy with
surgery
Authors and Disclosures Al B. Benson III, MD, FACP
Disclosure: Dr. Lenz: Grant/Research Support: Cancer Therapy Evaluation Program (CTEP), National Cancer Institute (NCI), National Health Institute (NHI), Southwest Oncology Group (SWOG). Consultant/Advisory Board: Amgen Inc.; Bristol-Myers Squibb
Company; Genentech, Inc.; ImClone Systems Incorporated; Merck & Co., Inc.; Novartis Pharmaceuticals; Pfizer Inc.; Response Genetics; sanofi-aventis. Speakers Bureau/Honorarium: Eli Lilly and Company; Merck & Co., Inc.; Pfizer Inc.; Roche; sanofi-aventis. Contracted Research: American Association for Cancer Research (AACR); Bristol-Myers Squibb Company; Celmed BioSciences Inc.; Cancer Therapy Evaluation Program (CTEP); Eisai Inc.;
Genentech, Inc.; Merck & Co., Inc.; National Cancer Institute (NCI); Novartis Pharmaceuticals; Pfizer Inc.; Roche; sanofi-aventis; Taiho Pharmaceutical Co., Ltd. Clinical Trials Support: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech Inc.; ImClone Systems Incorporated; Novartis Pharmaceuticals; Pfizer Inc.; Roche, sanofi-aventis. Al B. Benson III, MD, FACP
Disclosure: Dr. Benson has no disclosures to report. Axel Grothey, MD
Disclosure: Dr. Grothey: Grant/Research Support: Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Genentech, Inc.; sanofi-aventis.author had no financial interests to disclose at the time of publication. Leonard Saltz, MD
Disclosure: Dr.
Saltz: Grant/Research Support: Amgen Inc.; Genentech, Inc.; ImClone Systems Incorporated; Merck & Co., Inc.; Pfizer Inc.; Roche. Consultant/Advisory Board: Genentech, Inc.; ImClone Systems Incorporated; Merck & Co., Inc. Lakshmi Rajdev, MD
Disclosure: Dr. Rajdev: Speakers Bureau/Honorarium: Amgen Inc.; Genentech, Inc.;
sanofi-aventis. Steven J. Feld
Disclosure: Steven J. Feld, or a member of his household, owns securities in the following: Bioheart, Inc.; Chelsea Therapeutics, Inc.; and sanofi-aventis. |
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine & Montefiore Medical Center and M2 Communications, Inc. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
